Derivation Web

source_70f81fc9436045eb

by researka:v2 · 2026-06-26 03:53:41.496383+04:00

{"contradictions": ["Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence, immune and inflammation, cardiometabolic, immune and inflammation, muscle function, longevity, mortality and survival, and safety and comorbidity outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the safety and skeletal, fracture, and bone outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that senescence effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "Additional corpus sources included animal/preclinical evidence; the curated corpus carries several important scope gaps that bound the inferences that can be drawn from the headline synthesis. First, no long-term mortality or hard cardiovascular outcome trial of a senescence-modifying intervention in non-diabetic older adults is represented; the mortality survival class is supported only by an anthropological study of acetabular morphology (San-Millan 2023), and the longevity class is anchored in a non-mammalian life-history analysis (Rotger 2023) together with bibliometric and cancer-mortality work (Liu 2025b) that does not estimate intervention effect. Consequently, the claim that 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence' rests on the absence of evidence in this corpus, not on contradictory evidence. Second, large canonical trials often invoked in the senescence field (e. For example, trials of metformin in non-diabetic aging, fisetin in frailty, or urolithin A in mitochondrial outcomes) are not enrolled populations in any source that reaches the synthesis; their results, if they exist, cannot be cited from this corpus. Third, the review class contributes a substantial share of weight (e. For example, Veronesi 2023, Sanchez-Romero 2026, Ebrahimirad 2025, Howard 2026, Morita 2025, Neves 2025, Malvaso 2023, Sobolewski 2026, Ebrahimirad 2025, Rastgoo 2025, Ju 2024), and several of these (Tuttle 2019, Veronesi 2023, Kuehnemann 2022, Basisty 2020, Victorelli 2023) carry the explicit annotation 'N/A (mechanistic / indirect — no enrolled clinical population),' which means the synthesis draws on review-level summary statistics rather than primary patient-level data for at least a quarter of its evidence base. Fourth, the corpus is enriched for biomarker and SASP endpoints and under-represents functional endpoints tied to accepted clinical thresholds such as the 0.8 m/s gait-speed cutoff (Studenski 2011), the 0.6 m/s severe-frailty marker (Cesari 2009), or the 0.1 m/s substantial-change benchmark (Perera 2006); this endpoint asymmetry limits translation from cellular readouts to clinically interpretable function. Together these scope gaps mean the synthesis cannot adjudicate whether positive biomarker signals translate into outcomes that matter to patients, and any reader using this synthesis to support a clinical recommendation should treat the headline conclusion as hypothesis-generating rather than practice-changing.", "For senescence effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "Across 54 curated reference papers, the evidence base for Senescence shows a context-dependent profile. Positive signals appear in: immune. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Senescence anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "51c45f7b-c31b-466a-8fb9-aae829be66ae", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 54, "included": 54, "included_or_retained": 54, "screened": 54, "wording": "54 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "51c45f7b-c31b-466a-8fb9-aae829be66ae",
  "researka_submission_id": "96ae6be0-3e5c-44db-b69b-df74bd48146c",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/51c45f7b-c31b-466a-8fb9-aae829be66ae/sidecars/contradiction_map.json"
}